These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35238955)

  • 1. Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2022 May; 65(5):908-911. PubMed ID: 35238955
    [No Abstract]   [Full Text] [Related]  

  • 2. Ertugliflozin, renoprotection and potential confounding by muscle wasting.
    Groothof D; Post A; Gans ROB; Bakker SJL
    Diabetologia; 2022 May; 65(5):906-907. PubMed ID: 34940888
    [No Abstract]   [Full Text] [Related]  

  • 3. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
    J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
    Powell J; Garland SG
    Ann Pharmacother; 2019 May; 53(5):478-485. PubMed ID: 30522346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
    Hu J; Deng A; Zhao Y
    Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ertugliflozin: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):513-519. PubMed ID: 29476348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
    Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
    BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart K; Carris NW
    Expert Opin Pharmacother; 2021 Feb; 22(2):163-165. PubMed ID: 32962443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".
    Groothof D; Post A; Bakker SJL
    Circulation; 2022 Jul; 146(2):e5-e6. PubMed ID: 35858158
    [No Abstract]   [Full Text] [Related]  

  • 13. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
    Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Frederich R; Cherney DZI; Dagogo-Jack S; Pratley RE; Mancuso JP; Maldonado M; Cater NB; Wang S; McGuire DK
    Circulation; 2022 Aug; 146(8):652-654. PubMed ID: 35994565
    [No Abstract]   [Full Text] [Related]  

  • 17. Ertugliflozin + metformin as a treatment option for type 2 diabetes.
    Athyros VG; Boutari C; Karagiannis A
    Expert Opin Pharmacother; 2021 Nov; 22(16):2105-2111. PubMed ID: 34130582
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
    Heymsfield SB; Raji A; Gallo S; Liu J; Pong A; Hannachi H; Terra SG
    Obesity (Silver Spring); 2020 Apr; 28(4):724-732. PubMed ID: 32202075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials.
    Huang J; Xiong S; Ding S; Cheng Q; Liu Z
    J Diabetes Res; 2020; 2020():9704659. PubMed ID: 33532502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Frias JP
    Expert Rev Endocrinol Metab; 2019 Mar; 14(2):75-83. PubMed ID: 30724637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.